Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Akts | History Defined

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

MarketBeat

2 Tech Stocks to Buy This Week, 2 to Sell

Although the tech industry’s long-term prospects look bright amid robust demand, the industry might remain under pressure in the near term due to the macro headwinds. While investing in fundamentally sound stocks, Nokia Oyj (NOK) and Hewlett Packard Enterprise Company (HPE) could be beneficial, fundamentally weak, Akoustis Technologies (AKTS) and…

StockNews.com

2 Tech Stocks to Buy, 2 to Sell

The tech industry has witnessed a significant rebound stemming from transformational power and the broad application of AI. Thus, investing in fundamentally sound stocks Extreme Networks (EXTR) and PCTEL, Inc. (PCTI) could be beneficial. However, as the macroeconomic backdrop remains challenging, Akoustis Technologies (AKTS) and Ondas Holdings (ONDS) could be…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

What Do These 3 Tech Stocks Have in Common? They Need to Be Sold IMMEDIATELY

The tech sector is expected to keep struggling amid the high-interest-rate environment and the rising possibility of a recession. So, I believe Akoustis Technologies (AKTS), Mynaric AG (MYNA), and Ondas Holdings Inc. (ONDS) might be best avoided right now, considering their bleak fundamentals. Let’s discuss this in detail….

StockNews.com

Akoustis Technologies Earnings Perspective: Return On Invested Capital

According to data from Benzinga Pro, during Q3, Akoustis Technologies's (NASDAQ:AKTS) reported sales totaled $4.61 million. Despite a 2.76% increase in earnings, the company posted a loss of $14.82 million.

Benzinga

Akoustis Registers 83% Revenue Growth In Q3; Adds Another Tier-1 5G Mobile RF Module Customer

Akoustis Technologies, Inc (NASDAQ:AKTS) reported third-quarter FY22 revenue growth of 83% year-on-year (25% Q/Q) to $4.61 million, missing the consensus of $4.70 million. Non-GAAP EPS loss of $(0.27) missed the consensus loss of $(0.22). Akoustis held $55.9 million in cash and equivalents. CEO Jeff Shealy stated, "Despite the persistent macro headwinds presented by…

Benzinga

Recap: Akoustis Technologies Q3 Earnings

Akoustis Technologies (NASDAQ:AKTS) reported its Q3 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Organisations

Hewlett Packard Enterprise Company

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

376,167 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.